RF26 | PMON332 Safety and Efficacy of Treatment with Lonapegsomatropin in Children with Growth Hormone Deficiency at Week 130 in the enliGHten Trial

BACKGROUND: Once-weekly lonapegsomatropin (TransCon hGH) is a long-acting prodrug of somatropin, recently approved for the treatment of pediatric growth hormone deficiency (GHD) by the US FDA. In the pivotal 52-week phase 3 heiGHt trial and the 26-week fliGHt trial, lonapegsomatropin demonstrated sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Saenger, Paul, Nadgir, Ulhas, Hofman, Paul, Thornton, Paul, Chertok, Elena D, Aghajanova, Elena M, Korpal-Szczyrska, Maria, Vlachopapadopoulou, Elpis, Malievskiy, Oleg, Chaychenko, Tetyana, Cappa, Marco, Song, Wenjie, Mao, Meng, Chessler, Steven D, Komirenko, Allison S, Beckert, Michael, Shu, Aimee D, Maniatis, Aristides K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625565/
http://dx.doi.org/10.1210/jendso/bvac150.1334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625565/
http://dx.doi.org/10.1210/jendso/bvac150.1334

Ejemplares similares